J Bacteriol Virol.  2019 Mar;49(1):39-43. 10.4167/jbv.2019.49.1.39.

Delafloxacin, a New Miracle in Antibiotics Armamentarium for Bacterial Infections

• Rahman MS
• Koh YS

• KMID: 2442586
• DOI: http://doi.org/10.4167/jbv.2019.49.1.39

Abstract

The persistent antibiotics resistant issue has emerged as an influencing factor to deteriorate community health. So, new antibiotics development is urgent for the treatment of bacterial infections. Alternatively, delafloxacin is an eminent new fluoroquinolone, and chemically distinct from older fluoroquinolones. There is lack of proton substituent that indicates the poor acidic property of the drug. It also has a good intracellular penetration capacity that increases the intensity of the bactericidal property in acidic environment. Delafloxacin is a super active drug against the skin and soft tissue infections (SSTIs) and community-acquired respiratory tract infections. Delafloxacin also exhibits better efficacy against pathogens which are resistant to other fluoroquinolones, such as methicillin-resistant Staphylococcus aureus (MRSA). Delafloxacin received approval from the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSI). Phase III clinical trial among patients with community-acquired pneumonia (CAP) is ongoing to evaluate the effectiveness of delafloxacin. From the aforementioned arguments, delafloxacin will be a prominent candidate for the upcoming antibacterial agent. Similarly, delafloxacin can be a crucial drug to fight against ABSSI.

Keyword

Antibiotics; Delafloxacin; Fluoroquinolones; Acute bacterial skin and skin structure infections

MeSH Terms

Anti-Bacterial Agents*
Bacterial Infections*
Fluoroquinolones
Humans
Methicillin-Resistant Staphylococcus aureus
Pneumonia
Protons
Respiratory Tract Infections
Skin
Soft Tissue Infections
United States Food and Drug Administration
Anti-Bacterial Agents
Fluoroquinolones
Protons

Reference

1. Jorgensen SCJ, Mercuro NJ, Davis SL, Ryback MJ. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018; 7:197–217.

2. Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018; 73:1439–1451.

3. Candel FJ, Peñuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther. 2017; 11:881–891.

4. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55:649–658.

5. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, Devito JA. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012; 67:2814–2820.

6. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000; 31:Suppl 2. S24–S28.

7. Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003; 47:3260–3269.

8. O'Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin structure infections. Int J Infect Dis. 2015; 30:67–73.

9. Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016; 71:821–829.

10. Hoover R, Hunt T, Benedict M, Paulson SK, Lawrence L, Cammarata S, et al. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex and age. Clin Ther. 2016; 38:39–52.

11. Kashida Y, Kato M. Characterization of fluoroquinolone-induced achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother. 1997; 41:2389–2393.

12. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007; 41:1859–1866.

13. Rahman MS, Koh YS. Omadacycline, a magic antibiotics for bacterial infections. J Bacteriol Virol. 2018; 48:109–112.

14. Füzi M. Has the use of fluoroquinolones facilitated the widespread dissemination of methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in the healthcare setting? Acta Microbiol Immunol Hung. 2014; 61:399–405.

15. Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013; 57:2726–2737.

16. Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O, Van Bambeke F. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2014; 58:6385–6397.

17. Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016; 48:535–541.

18. Baudry-Simner PJ, Singh A, Karlowsky JA, Hoban DJ, Zhanel GG, Canadian Antimicrobial. Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals. Can J Infect Dis Med Microbiol. 2012; 23:e60–e64.